Plus Therapeutics Receives Orphan Drug Designation to Rhenium (186Re) Obisbemeda

DENVER, Colo., Nov 3, 2023 ( Plus Therapeutics, Inc. (Nasdaq: PSTV) stated, this morning, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to rhenium (186Re) obisbemeda for the treatment of breast cancer with leptomeningeal metastases (LM).

Plus Therapeutics is trading at $1.41, up $0.04 (+2.92%), on 218.1K premarket shares traded.

Its 52-week range is $0.9694 to $7.4985. It hit a new 52-week low last week and its next resistance points are yesterday’s high of $1.54 and $1.60, and if it can break through those during the regular trading session, on very strong volume, its setup could allow it to run much higher.

 24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist